国产紫杉醇联合方案治疗晚期非小细胞肺癌38例

Result of Chemotherapy Integrated With Paclitaxel in Advanced NSCLC

目的 观察国产紫杉醇联合方案对晚期非小细胞肺癌的疗效及副反应。方法 38例晚期非小细胞肺癌应用国产紫杉醇135mg/m2加卡铂300mg/m2或DDP80mg/m2联合方案化疗。结果 38例中CRI例、PR15例、NC17例、PD5例,总有效率42.1％。16例初治者,PR8 例,有效率50％。22例复治者有效率36.4％。全组缓解期2～6月,中位缓解期3月,中位生存期10月,1年生存率为36％。主要副反应为骨髓抑制及消化道反应。结论 以国产紫杉醇为主联合方案治疗晚期非小细胞肺癌有较高疗效,特别是对复发病例也有较好疗效,毒副反应可以耐受。

OBJECTIVE To study the result and side effects of chemotherapy integrated with Paclitaxel in advanced non-small cell lung carcinoma (NSCLC). METHODS 38 cases of advanced NSCLC were treated with Paclitaxel (135mg/m2) and with OBP(300mg/m2) or DDP(80mg/m2). RESULT Among 38 cases ,CR covered 1 cases,PR covered 15 cases, NC covered 17 cases and PD covered 5 cases, the total effective rate was 42. 1%. Among 16 cases for the first treatment. PR covered 8 cases and the effective rate 50%. The effective rate of 22cases was 36. 4% for the second treatment. The relieve period of whold group was 2 to 6 months. The mean relieve period was 3 months was 36%. The main side effects were bone marrow suppression and the effect of digestive tract CONCLUSION Chemotherapy integrated mainly with paclitaxel had better result in advanced NSCLC, especially in the recurrent cases, and its side effects can be tolerated.